RGLS vs. BCRX, FOLD, CLDX, INVA, DVAX, MNKD, NVAX, OPK, GERN, and MYGN
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.
Regulus Therapeutics vs. Its Competitors
Regulus Therapeutics (NASDAQ:RGLS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
Regulus Therapeutics has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 4.17%. BioCryst Pharmaceuticals has a consensus target price of $16.70, indicating a potential upside of 86.70%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Regulus Therapeutics.
Regulus Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -10.62%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Regulus Therapeutics' return on equity.
In the previous week, BioCryst Pharmaceuticals had 34 more articles in the media than Regulus Therapeutics. MarketBeat recorded 37 mentions for BioCryst Pharmaceuticals and 3 mentions for Regulus Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.29 beat Regulus Therapeutics' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Regulus Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
Summary
BioCryst Pharmaceuticals beats Regulus Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RGLS) was last updated on 7/3/2025 by MarketBeat.com Staff
